Neisserial vaccine compositions and methods

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S069700, C435S069300, C435S071100, C435S071200, C435S071300, C435S320100, C435S252100, C424S184100, C514S002600

Reexamination Certificate

active

09942583

ABSTRACT:
Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensalNeisseriaor an extract of a commensalNeisseria. Further methods and compositions comprise commensalNeisseriawhich express genes from virulent strains ofNeisseriaand/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.

REFERENCES:
patent: 5470740 (1995-11-01), Longo et al.
patent: 5980912 (1999-11-01), Podolski et al.
patent: 6013267 (2000-01-01), Blake et al.
patent: 6413768 (2002-07-01), Galen
patent: 6703233 (2004-03-01), Galen
patent: 6737521 (2004-05-01), Fischetti et al.
patent: 2003/0021812 (2003-01-01), Robinson et al.
patent: 2003/0026809 (2003-02-01), Robinson et al.
patent: 2003/0215469 (2003-11-01), Robinson et al.
patent: 2005/0013831 (2005-01-01), Foster et al.
patent: 1297844 (2003-04-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO99/61620 (1999-12-01), None
patent: WO 03/051379 (2003-06-01), None
Moe etal, Infection and Immunity 70/11: 6021-6031, Nov. 2002.
Martin etal, J. Exp. Med. 185/7: 1173-1183, Apr. 1997.
Oliver et al, Infection and Immunity 70/7: 3621-3626, Jul. 2002.
Parkhill et al, Nature 404: 502-506, Mar. 2002.
Gómez etal, Vaccine, 16/17: 1633-1639, 1998.
Ala'Aldeen etal, J. Med. Microbiology 44:237-43, 1996.
Moe etal, Infection and Immunity 67/11: 5664-5675, Nov. 1999.
Fusco etal, Exp. Opin. Invest. Drugs 7/2: 245-252, 1998.
Moe etal, FEMS Immunology+Med. Microbiology 26:209-226, 1999.
Pettit et al, Can. J. Microbiol 47:871-876, 2001.
Grifantini etal, Ann. N.Y. Acad. Sci. 975: 202-216, 2002.
Zhou et al, Molecular Microbiology 23/4: 799-812, 1997.
Pannekock etal, Molecular Microbiology 15/2: 277-285, 1995.
Linz et al, Molecular Microbiology 36/5: 1049-1058.
Evans, Dissertation Abstracts International, 1989, vol. 50/08-B, p. 3315.
Mielcarek et al, Advanced Drug Delivery Reviews, 2001, 51, 55-69.
Sanchez et al, Vaccine, 2001, 19:3390-3398.
O'Dwyer et al, Infection and Immunity, Nov. 2004, 72/11:6511-6518.
Gorringe et al, Vaccine, 2005, 23:2210-2213.
Bennett et al, Infection and Immunity, Apr. 2005, 73/4:2424-2432.
Pollard et al, Vaccine, 2001, 19:1327-1346.
Mukhopadhyay et al, Biotechnol. Appl. Biochem., 2005, 41:175-182.
Jodar et al, Lancet, 2002, 359:1499-1508.
Oftung et al, FEMS Immunology and Medical Microbiology, 1999, 26:75-82.
Serruto et al, J. Biotechnology, 2004, 113:15-32.
Locht, PSTT, Apr. 2000, 3/4:121-128.
Humphries et al, Vaccine, 2004, 22:1564-1569.
Medaglini et al, Vaccine, 1997, 15/(12/13):1330-1337.
Ellis, Vaccine, 1999, 17:1596-1604.
Aho et al, Infection and Immunity, Jul. 1997, 65/7:2613-2620.
Tettelin et al, Science, 2000, 287:1809-1815.
Gotschlich et al, J. Exp. Med., 1986, 164:868-881.
Johnson et al, Infection and Immunity, Jul. 1996, 64/7:2627-2634.
Goh et al, Antonie can Leeuwenhock et al, 2005, 87:205-213.
Claassen et al, Vaccine, 14/10:1001-1008.
Aho et al, Microbial Pathogenesis, 2000, 28:81-88.
Toleman et al, Cellular Microbiology, 2001, 3/1:33-44.
Troncoso et al, FEMS Microbioogy Letters, 2001, 199:171-176.
van der Ley et al, Infection and Immunity, Aug. 1992, 60/8:3156-3161.
van der Ley et al, Infection and Immunity, Oct. 1993, 61/10:4217-4224.
Ferreiros et al, FEMS Microbiology Letters, 1991, 83:247-254.
Cann, K. J. and Rogers, T.R., “Detection of antibodies to common antigens of pathogenic and commensalNeisseriaspecies,”J. Med. Microbiol.30:23-30, The Pathological Society of Great Britain and Ireland (1989).
Gómez, J.A. et al., “Antigenicity, cross-reactivity and surface exposure of theNeisseria meningitidis37 kDa protein (Fbp),”Vaccine14:1340-1346, Elsevier Science Ltd (1996).
English abstract of Aoun, L. et al., “Human Antibody Response to the 70-KD Common Neisserial Antigen in Patients and Carriers ofMeningococcior Non-PathogenicNeisseria,” Annales de l'Institut Pasteur Microbiology139:203-212, Biosis Online accession No. PREV198886026860, XP-0021498186(1988).
Troncoso, G. et al., “Antigenic cross-reactivity between outer membrane proteins ofNeisseria meningitidisand commensalNeisseriaspecies,”FEMS Immunol. Med. Microbiol.27:103-109, Elsevier Science B.V. (Feb. 2000).
U.S. Appl. No. 10/185,769, filed Jul. 1, 2002, Robinson et al., mailed Nov. 28, 2003.
U.S. Appl. No. 10/185,769, filed Jul. 1, 2002, Robinson et al., mailed Jun. 18, 2004.
Hoehn, G.T. and Clark, V.G. “Distribution of a Protein Antigenically Related to the Major Anaerobically Induced Gonococcal Outer Membrane Protein among OtherNeisseriaSpecies,”Infection and Immunity58:3929-3933, American Society for Microbiology (1990).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Neisserial vaccine compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neisserial vaccine compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neisserial vaccine compositions and methods will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3819570

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.